Moderate-to-Severe Dry Eye Disease Relief Using Acoltremon

To evaluate the impact of Acoltremon 0.003% on subjective dry eye symptoms using validated patient-reported outcome measures: Eye Dryness Score Visual Analog Scale (EDS-VAS). The primary aim is to characterize the rapidity of symptomatic relief in moderate to severe dry eye disease (DED), with attention to short-term therapy.

NCT Number	NCT07268599
Lead Sponsor	Colvard Kandavel Eye Center
Conditions	Dry Eye Disease (DED)
Enrollment	50 participants
Start Date	2025-11-24
Primary Completion	2026-10 (estimated)
Study Completion	2026-10 (estimated)
Updated on ClinicalTrials.gov	2025-12-08